Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors

BACKGROUND: To extend the discussion on the use of real-world evidence (RWE) in conveying the clinical value of treatment beyond trial data, the primary objective of this study was to assess if efficacy gains in progression-free survival (PFS) observed in randomized controlled trials (RCT) correlate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaitonde, Priyanka, Chirikov, Viktor, Kelkar, Sneha, Liljas, Bengt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741849/
https://www.ncbi.nlm.nih.gov/pubmed/36514307
http://dx.doi.org/10.2147/CMAR.S380857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741849/
https://www.ncbi.nlm.nih.gov/pubmed/36514307
http://dx.doi.org/10.2147/CMAR.S380857

Ejemplares similares